1. Home
  2. HLXB vs NMRA Comparison

HLXB vs NMRA Comparison

Compare HLXB & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLXB
  • NMRA
  • Stock Information
  • Founded
  • HLXB 2021
  • NMRA 2019
  • Country
  • HLXB United States
  • NMRA United States
  • Employees
  • HLXB N/A
  • NMRA N/A
  • Industry
  • HLXB
  • NMRA
  • Sector
  • HLXB
  • NMRA
  • Exchange
  • HLXB NYSE
  • NMRA Nasdaq
  • Market Cap
  • HLXB 255.2M
  • NMRA 234.5M
  • IPO Year
  • HLXB 2024
  • NMRA 2023
  • Fundamental
  • Price
  • HLXB $10.70
  • NMRA $2.35
  • Analyst Decision
  • HLXB
  • NMRA Buy
  • Analyst Count
  • HLXB 0
  • NMRA 8
  • Target Price
  • HLXB N/A
  • NMRA $7.14
  • AVG Volume (30 Days)
  • HLXB 88.8K
  • NMRA 2.6M
  • Earning Date
  • HLXB 01-01-0001
  • NMRA 08-06-2025
  • Dividend Yield
  • HLXB N/A
  • NMRA N/A
  • EPS Growth
  • HLXB N/A
  • NMRA N/A
  • EPS
  • HLXB 0.26
  • NMRA N/A
  • Revenue
  • HLXB N/A
  • NMRA N/A
  • Revenue This Year
  • HLXB N/A
  • NMRA N/A
  • Revenue Next Year
  • HLXB N/A
  • NMRA N/A
  • P/E Ratio
  • HLXB $41.92
  • NMRA N/A
  • Revenue Growth
  • HLXB N/A
  • NMRA N/A
  • 52 Week Low
  • HLXB $10.28
  • NMRA $0.61
  • 52 Week High
  • HLXB $11.59
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • HLXB N/A
  • NMRA 85.38
  • Support Level
  • HLXB N/A
  • NMRA $1.70
  • Resistance Level
  • HLXB N/A
  • NMRA $2.17
  • Average True Range (ATR)
  • HLXB 0.00
  • NMRA 0.30
  • MACD
  • HLXB 0.00
  • NMRA 0.11
  • Stochastic Oscillator
  • HLXB 0.00
  • NMRA 74.95

About HLXB HELIX ACQUISITION CORP. II

Helix Acquisition Corp II is a Blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: